Alzheimer's: Bapineuzumab and Solanezumab
Survey shows dim faith in Lilly, Pfizer Alzheimer's drugs
Ransdell Pierson | Reuters
The Chicago Tribune
June 19, 2012
[snip]
"Results from the survey of 146 investors were released late on Tuesday by Mark Schoenebaum, a pharmaceutical analyst for the investment research services group. Wall Street is eagerly awaiting results of the trials and expects huge potential sales if either of the medicines proves able to arrest the progression of the memory-robbing disease.
"Pfizer and Lilly are expected in the third quarter to disclose the main findings from large studies of their respective medicines, bapineuzumab and solanezumab. Complete data are expected to be presented at medical meetings in the fourth quarter.
"The survey responders, on average, gave solanezumab only a 14 percent chance of meeting all the primary goals of its two Phase III studies, compared with an average 21 percent probability for the two big trials of bapineuzumab, Schoenebaum said."
[snip]
Read the full article
Comments by the Pharmalot blog on this report, from the 20th of June:
Read the blog entry from Pharmalot.
- Alzheimer: Clinical Trials Day At The Aaic2015 Conference
Alzheimer's Association Press Release at 0700 hrs EDT on 22 July 2015. - Longer-Term Analysis of Phase 3 Solanezumab (Lilly) Up to 3.5 Years - Biomarker Results from Phase 3 Gantenerumab (Roche) Trial - New Data from Aducanumab (Biogen) Phase 1b...
- Alzheimer's Disease: A Wrap For Bap
Trials for Alzheimer’s Drug Halted After Poor Results By KATIE THOMAS The New York Times 06 August 2012 Read full article ---Corporate Press Release: Read the releaseCommentary from the In The Pipeline blog: In The PipelineCommentary from Pharmalot:...
- Alzheimer's Disease: Negative Bapineuzumab Findings In Phase Iii Trial
Critical reading for those interested in Alzheimer's clinical trials: first results from the BAP Phase III program. The link includes additional links to a New York Times article and a company press release. From FierceBiotech: UPDATED: Pfizer, J&J...
- Amyvid Approval
From Pharmalot blog, a good read about the Amyvid approval decision: Should FDA Have Approved Lilly Alzheimer’s Agent? Pharmalot By Ed Silverman April 9th, 2012 // 11:23 am Read the full blog post...
- Alzheimer Disease: Dimebon Results
A press release from earlier today by Pfizer: Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine) Alzheimer’s Disease Clinical Development Program [snip] "About the CONNECTION Study "CONNECTION is a Phase 3, multi-national,...